HIV & Shingles Vaccine Study
Adults on antiretroviral therapy for HIV who have not received the Shingrix vaccine may be eligible to participate in a compensated research study.
Fast Facts
Adult on antiretroviral therapy for HIV
Have not received the Shingrix vaccine
Compensation
provided
Conducted in
Bethesda, MD
Study Background
Understanding Shingrix in People with HIV
People living with HIV may have a higher risk of shingles, a painful condition caused by the reactivation of the chickenpox virus. Shingrix is a recombinant vaccine that helps protect against shingles, but its immune response in people with HIV is not yet fully understood. This study is designed to evaluate how individuals with HIV respond to the Shingrix vaccine over time.
Participants will receive two doses of the vaccine, given two months apart, and will return for follow-up visits at months 3 and 12. At each visit, researchers will monitor safety through physical exams, blood tests, and health questionnaires. By participating, volunteers will contribute to valuable research that could improve vaccine recommendations and long-term health outcomes for people living with HIV.
Study Background
Understanding Shingrix in People with HIV
People living with HIV may have a higher risk of shingles, a painful condition caused by the reactivation of the chickenpox virus. Shingrix is a recombinant vaccine that helps protect against shingles, but its immune response in people with HIV is not yet fully understood. This study is designed to evaluate how individuals with HIV respond to the Shingrix vaccine over time.
Participants will receive two doses of the vaccine, given two months apart, and will return for follow-up visits at months 3 and 12. At each visit, researchers will monitor safety through physical exams, blood tests, and health questionnaires. By participating, volunteers will contribute to valuable research that could improve vaccine recommendations and long-term health outcomes for people living with HIV.
Additional Information
This study is being done to learn how well the Shingrix vaccine works in people living with HIV and to monitor safety and immune response.
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Adults with HIV
- On antiretroviral therapy for at least 6 months
- Have not taken the Shingrix vaccine
- No uncontrolled medical, neurological, or psychiatric conditions
- Not currently pregnant, breastfeeding, or planning to become pregnant soon
- Willing to commit to 5 study visits over 1 year, including blood draws, physical exams, and vaccine visits
If you join the study, you will attend 5 visits over the course of 1 year. This includes a screening visit, two vaccination visits, and two follow-up visits. At each visit, you will have your vital signs taken, blood drawn, and a physical exam.
Participants will be compensated throughout the year as visits are completed. Travel reimbursement may also be available for some participants.
There is no cost for you to participate in our research study.